| Title |
TBCRC 018: phase II study of iniparib in combination with irinotecan to treat progressive triple negative breast cancer brain metastases
|
|---|---|
| Published in |
Breast Cancer Research and Treatment, July 2014
|
| DOI | 10.1007/s10549-014-3039-y |
| Pubmed ID | |
| Authors |
Carey Anders, Allison M. Deal, Vandana Abramson, Minetta C. Liu, Anna M. Storniolo, John T. Carpenter, Shannon Puhalla, Rita Nanda, Amal Melhem-Bertrandt, Nancy U. Lin, P. Kelly Marcom, Catherine Van Poznak, Vered Stearns, Michelle Melisko, J. Keith Smith, Olga Karginova, Joel Parker, Jonathan Berg, Eric P. Winer, Amy Peterman, Aleix Prat, Charles M. Perou, Antonio C. Wolff, Lisa A. Carey |
| Abstract |
Nearly half of patients with advanced triple negative breast cancer (TNBC) develop brain metastases (BM) and most will also have uncontrolled extracranial disease. This study evaluated the safety and efficacy of iniparib, a small molecule anti-cancer agent that alters reactive oxygen species tumor metabolism and penetrates the blood brain barrier, with the topoisomerase I inhibitor irinotecan in patients with TNBC-BM. Eligible patients had TNBC with new or progressive BM and received irinotecan and iniparib every 3 weeks. Time to progression (TTP) was the primary end point; secondary endpoints were response rate (RR), clinical benefit rate (CBR), overall survival (OS), toxicity, and health-related quality of life. Correlative endpoints included molecular subtyping and gene expression studies on pre-treatment archival tissues, and determination of germline BRCA1/2 status. Thirty-seven patients began treatment; 34 were evaluable for efficacy. Five of 24 patients were known to carry a BRCA germline mutation (4 BRCA1, 1 BRCA2). Median TTP was 2.14 months and median OS was 7.8 months. Intracranial RR was 12 %, while intracranial CBR was 27 %. Treatment was well-tolerated; the most common grade 3/4 adverse events were neutropenia and fatigue. Grade 3/4 diarrhea was rare (3 %). Intrinsic subtyping revealed 19 of 21 tumors (79 %) were basal-like, and intracranial response was associated with high expression of proliferation-related genes. This study suggests a modest benefit of irinotecan plus iniparib in progressive TNBC-BM. More importantly, this trial design is feasible and lays the foundation for additional studies for this treatment-refractory disease. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 94 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 1 | 1% |
| Belgium | 1 | 1% |
| Unknown | 92 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 14 | 15% |
| Student > Bachelor | 13 | 14% |
| Other | 9 | 10% |
| Student > Ph. D. Student | 5 | 5% |
| Professor | 4 | 4% |
| Other | 17 | 18% |
| Unknown | 32 | 34% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 26 | 28% |
| Agricultural and Biological Sciences | 12 | 13% |
| Biochemistry, Genetics and Molecular Biology | 9 | 10% |
| Nursing and Health Professions | 6 | 6% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 3% |
| Other | 4 | 4% |
| Unknown | 34 | 36% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 08 August 2014.
All research outputs
#18,375,478
of 22,759,618 outputs
Outputs from Breast Cancer Research and Treatment
#3,712
of 4,652 outputs
Outputs of similar age
#161,603
of 225,828 outputs
Outputs of similar age from Breast Cancer Research and Treatment
#34
of 49 outputs
Altmetric has tracked 22,759,618 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 4,652 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.2. This one is in the 11th percentile – i.e., 11% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 225,828 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 15th percentile – i.e., 15% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 49 others from the same source and published within six weeks on either side of this one. This one is in the 12th percentile – i.e., 12% of its contemporaries scored the same or lower than it.